Macrophage membrane-encapsulated liposomes of protopanaxadiol-type doxorubicin hydrochloride improve formulation stability for the treatment of triple-negative breast cancer | Synapse
Macrophage membrane-encapsulated liposomes of protopanaxadiol-type doxorubicin hydrochloride improve formulation stability for the treatment of triple-negative breast cancer
Key Points
This research aims to investigate how macrophage membrane-encapsulated liposomes can stabilize doxorubicin for treating triple-negative breast cancer.
Conducted in vitro experiments to assess formulation stability.
Performed in vivo studies to evaluate antitumor effects.
Used doxorubicin hydrochloride encapsulated in liposomes combined with protopanaxadiol.
Found that DOX-(PPD)-LIP@M significantly improves the stability of the drug formulation.
Observed an enhanced antitumor effect compared to standard doxorubicin treatment.
Abstract
In vitro and in vivo experiments demonstrated that DOX-(PPD)-LIP@M improves formulation stability and enhances the antitumor effect of DOX.